- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04462471
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Alan L Ho, MD, PhD
- Phone Number: 646-608-3774
- Email: hoa@mskcc.org
Study Contact Backup
- Name: James A Fagin, MD
- Phone Number: 646-888-2136
- Email: faginj@mskcc.org
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
-
Middletown, New Jersey, United States, 07748
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
Montvale, New Jersey, United States, 07645
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
-
New York
-
Commack, New York, United States, 11725
- Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)
-
Harrison, New York, United States, 10604
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center (All protocol activities)
-
Rockville Centre, New York, United States, 11553
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary, follicular, and poorly differentiated subtypes and their respective variants).
- A tumor sample (primary, recurrent, or metastatic tumors) possessing a BRAF V600 mutation, as confirmed in a CLIA-certified laboratory or using an FDA-approved assay
- Measurable disease by RECIST v1.1 (tumors in previously irradiated fields may be considered measurable if there is evidence of tumor progression after radiation treatment)
RAIR disease, as defined by any one of the following:
- A metastatic lesion that is not RAI-avid on a diagnostic radioiodine scan
- An RAI-avid lesion that remained stable in size or progressed despite RAI treatment before entry in this study (there are no size limitations for the index lesion used to satisfy this entry criterion)
- The presence of at least 1 FDG-avid lesion
No receipt of treatment for thyroid cancer, defined as:
- No I-131 therapy < 6 months before initiation of the protocol (time of initiation of the protocol is defined as the first day of drug therapy with vemurafenib and copanlisib); diagnostic activities of I-131 (0-10m Ci) are allowed within 6months of initiating the protocol
- No external beam radiation therapy <4 weeks before initiation of the protocol
- No chemotherapy or targeted therapy including TKIs <4 weeks (or <5 half lives of the drug) before the initiation of this protocol
- Age of ≥ 18 years
- ECOG performance status ≤ 2 or Karnofsky Performance Score (KPS) ≥ 70%
- Tissue from the primary tumor or metastases available for correlative studies. Either a paraffin block or at least 20 unstained slides are acceptable (30 unstained slides is ideal); if <20 unstained slides are available, and a paraffin block is not available, the patient may be able to participate at the discretion of the investigator
- Able to swallow and retain an orally administered pill without any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowels
- Agree to undergo 2 research biopsies of (a) malignant lesion(s). Tumor tissue obtained before study consent or treatment can also be submitted in lieu of performance of the first pretreatment biopsy if the Principal Investigator deems it to be of sufficient quantity/quality/timeliness (tumor tissue obtained more than 3 years from time of study consent would not be eligible). Patients may be exempt from biopsy if (1) the investigator or person performing the biopsy judges that no tumor is accessible for biopsy, (2) the investigator or person performing the biopsy feels that the biopsy poses too great of a risk to the patient, or (3) the patient's platelet count is <100,000/mcL or the patient cannot be safely removed from anticoagulation therapy (if the anticoagulation therapy needs to be temporarily held for the biopsy procedure). If the investigator deems a second research biopsy to be high risk, the patient may be exempt from the second biopsy.
Screening laboratory values meeting the following criteria:
- WBC ≥ 2000/µL
- Neutrophils ≥ 1500/µL
- Platelets ≥ 100 × 10^3/µL
- Hemoglobin >9.0 g/dL
- Lipase ≤ 1.5 × ULN
- AST/ALT ≤ 3 × ULN
- Total bilirubin ≤ 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin <3.0 mg/dL)
- Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula below):
Female CrCl = (140 - age in years) x weight in kg x 0.85 / 82 x serum creatinine in mg/dL
Male CrCl = (140 - age in years) x weight in kg x 1.00 / 72 x serum creatinine in mg/dL
Exclusion Criteria:
- Untreated metastatic brain or leptomeningeal tumors (metastatic brain or leptomeningeal tumors treated with radiation and/or surgery are allowed)
- Prior malignancy if diagnosed and treated within 2 years of trial drug initiation (with the exception of nonmelanoma skin cancers or Stage I cancers treated with curative intent).Patients may be included if they have completed therapy for a prior malignancy >2 years before drug initiation and currently have no evidence of disease
- Inability to follow a low-iodine diet or requiring a medication with a high content of iodide (amiodarone)
- Current congestive heart failure class >2, as defined by the New York Heart Association functional classification system
- Myocardial infarction < 6 months before the initiation of protocol
- Unstable angina (angina symptoms at rest) or new-onset angina (begun within the last 3 months)
- Uncontrolled hypertension (blood pressure >150/90, despite optimal medical management)
- Uncontrolled type I or II diabetes mellitus, as judged by the investigator, or Hgb A1C of >8.5
- Arterial or venous thrombotic event or embolic event, such as a cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism, within 3 months before the start of study medication
- Nonhealing wound, ulcer, or bone fracture (tumor-related nonhealing wounds are allowed)
- Active, clinically serious infections CTCAE v5.0 grade >2
- History of concurrent condition of interstitial lung disease and/or severely impaired lung function
- Known history of HIV infection (all patients must be screened for HIV up to 28 days before start of study)
- Seizure disorder requiring medication
- Therapy with a prohibited concomitant medication that cannot be temporarily held (at least 2 weeks before initiation of vemurafenib plus copanlisib until 1 week after the last dose) or replaced with a nonprohibited concomitant medication
- Systemic corticosteroid therapy at a daily dose >15 mg prednisone or equivalent (previous corticosteroid therapy must be stopped or reduced to the allowed dose at least 7 days before study registration)
- Cytomegalovirus (CMV) PCR-positive at baseline
- Evidence or history of a bleeding diathesis or any hemorrhage or bleeding CTCAE v5.0 grade ≥ 3 within 4 weeks before the start of study protocol
- HBV or HCV infection. All patients must be screened for HBV and HCV up to 28 days before the start of study medication using the routine hepatitis virus laboratorial panel. Patients positive for HBsAg or HBcAb will be eligible if they are negative for HBV-DNA (these patients should receive prophylactic HBV antiviral therapy). Patients positive for anti-HCV antibody will be eligible if they are negative for HCV-RNA
- Known hypersensitivity to any of the test drugs, test drug classes, or excipients in the formulation
- Substance abuse or medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
- Patients who are pregnant
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 6 months after the last administration of study treatment. Highly effective contraception methods include:
- Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception
- Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks before taking study treatment. In cases of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone-level assessment (FSH level in the postmenopausal range) is this acceptable
- Male sterilization (at least 6 months before screening). The vasectomized male partner should be the sole partner for that patient
- Use of oral, injected, or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system or other forms of hormonal contraception that have comparable efficacy (failure rate <1%)-for example, hormone vaginal ring or transdermal hormone contraception. Note: In cases of use of oral contraception, women should have been stable, on the same pill for a minimum of 3 months before taking study treatment
- Women are considered postmenopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks ago. In cases of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone-level assessment is she considered not of child-bearing potential.
- Sexually active men, unless they use a condom during intercourse while on treatment and for 6 months after stopping treatment with study drugs (men should not father a child in this period). A condom is required to be used by vasectomized men as well during intercourse to prevent delivery of the drug via semen.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Participants with thyroid cancer
Eligible participants will have a diagnosis of BRAF mutant RAIR thyroid cancer
|
I-124 PET/CT scans will be performed during this process to quantify baseline RAI avidity in index metastatic lesion(s)
Dose level 1 & 2: 960 mg PO bid Dose level -1: 720 mg PO bid Dose level -2: 480 mg PO bid
Dose level 2: 60 mg IV weekly Dose level 1, -1, -2: 45 mg IV weekly
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose of vemurafenib plus copanlisib
Time Frame: 6 months
|
The primary objective of this study is to determine the MTD of vemurafenib plus copanlisib inpatients with advanced BRAF mutant RAIR thyroid cancer.
The MTD is defined as the highest dose at which no more than 1 of 6 patients treated at that dose experience a DLT.
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Alan L Ho, MD, PhD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Head and Neck Neoplasms
- Adenocarcinoma, Papillary
- Thyroid Diseases
- Thyroid Neoplasms
- Thyroid Cancer, Papillary
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Vemurafenib
Other Study ID Numbers
- 20-053
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid Cancer, Papillary
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage II Papillary Thyroid Cancer | Stage III Papillary Thyroid Cancer | Stage I Papillary Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI); GlaxoSmithKline; National Comprehensive Cancer...CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
University Health Network, TorontoUniversity of British Columbia; Canadian Institutes of Health Research (CIHR); CHU de Quebec-Universite Laval and other collaboratorsRecruitingPapillary Thyroid Carcinoma | Papillary Thyroid Cancer | Papillary Microcarcinoma of the ThyroidCanada
-
National Cancer Institute (NCI)TerminatedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Anaplastic Thyroid Cancer | Stage III Follicular Thyroid Cancer | Stage III Papillary Thyroid CancerUnited States
-
Mayo ClinicActive, not recruitingPapillary Thyroid Cancer | Papillary Thyroid MicrocarcinomaUnited States
-
National Cancer Institute (NCI)CompletedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
-
Grupo Espanol de Tumores NeuroendocrinosMFARActive, not recruitingMetastatic Thyroid Cancer | Metastatic Thyroid Papillary Carcinoma | Metastatic Thyroid Follicular CarcinomaSpain
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
-
Massachusetts General HospitalCompletedPapillary Carcinoma of Thyroid Gland | Metastatic Medullary Thyroid Cancer | Follicular Thyroid Cancer Lymph Node MetastasisUnited States
Clinical Trials on I-124 PET/CT lesion dosimetry
-
Peregrine PharmaceuticalsTerminatedMalignant Solid TumorUnited States
-
Leiden University Medical CenterRecruitingDifferentiated Thyroid CancerNetherlands
-
prof. dr. Koen Van LaereUniversitaire Ziekenhuizen KU Leuven; KU Leuven; University Hospital, Ghent; Fund...Not yet recruitingParkinson Disease | Alzheimer Disease | Dementia With Lewy Bodies | MSA - Multiple System AtrophyBelgium
-
Royal Marsden NHS Foundation TrustCompletedExposure to Medical Diagnostic RadiationUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterRecruitingThyroid Carcinoma | Metastatic Thyroid CarcinomaUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedGlioblastoma | Brain MetastasesUnited States
-
Asan Medical CenterTerminatedPheochromocytoma | ParagangliomaKorea, Republic of
-
Jena University HospitalGE HealthcareUnknownThyroid Diseases | Thyroid Nodule | Thyroid GoitreGermany
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid... and other conditionsUnited States
-
Stanford UniversityTerminatedBreast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer Metastatic Breast CancerUnited States